Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clearside Biomedi (CLSD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,350
  • Shares Outstanding, K 32,024
  • Annual Sales, $ 350 K
  • Annual Income, $ -58,980 K
  • 36-Month Beta -1.30
  • Price/Sales 797.73
  • Price/Cash Flow N/A
  • Price/Book 1.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.56
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.76
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +13.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.09 +36.70%
on 01/29/19
1.90 -21.58%
on 02/20/19
+0.37 (+33.04%)
since 01/22/19
3-Month
0.99 +50.51%
on 12/27/18
1.92 -22.40%
on 11/23/18
-0.31 (-17.22%)
since 11/21/18
52-Week
0.99 +50.51%
on 12/27/18
15.33 -90.28%
on 05/30/18
-4.83 (-76.42%)
since 02/22/18

Most Recent Stories

More News
Thinking about buying stock in ARCA biopharma, Clearside Biomedical, Kandi Technologies, Nike or Tahoe Resources?

InvestorsObserver issues critical PriceWatch Alerts for ABIO, CLSD, KNDI, NKE, and TAHO.

TAHO : 3.64 (-3.96%)
CLSD : 1.50 (-0.66%)
NKE : 84.45 (+0.60%)
KNDI : 8.88 (+2.30%)
Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (NASDAQ:CSCO),...

ZEN : 78.42 (+1.76%)
CSCO : 49.97 (+1.13%)
CONN : 22.62 (+1.30%)
CLSD : 1.50 (-0.66%)
EGOV : 17.33 (+0.35%)
CVGI : 8.29 (+0.85%)
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE(TM) (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received...

CLSD : 1.50 (-0.66%)
Clearside Biomedical's Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society

- Presentations highlighted data analyses across multiple disease states -

CLSD : 1.50 (-0.66%)
Healthcare Companies Positioned in Major Markets

HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Pain relief medicines are a massive market 30 billion doses of which are consumed each year in the US alone. Opioids like codeine and hydrocodone are also...

CLSD : 1.50 (-0.66%)
APHA : 10.14 (-2.31%)
IVC : 9.82 (+1.55%)
Global Ocular Drug Delivery Technology Market Business Opportunities, Leading Players, Trends Outlook Up to 2026

Eye diseases such as cataract, glaucoma, diabetic retinopathy etc. are not treatment properly may cause loss of vision. Manufacturers are developing several novel technologies for ocular drug delivery...

VRX.TO : 30.80 (-3.33%)
CLSD : 1.50 (-0.66%)
AGN : 136.83 (+0.17%)
NVS : 90.61 (+0.11%)
PFE : 42.97 (+1.97%)
Clearside Biomedical Submits New Drug Application for XIPERE(TM) for the Treatment of Macular Edema Associated with Uveitis

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has...

CLSD : 1.50 (-0.66%)
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial...

CLSD : 1.50 (-0.66%)
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its...

CLSD : 1.50 (-0.66%)
Today's Research Reports on Stocks to Watch: Teladoc Health and Clearside

NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in...

TDOC : 69.00 (+1.10%)
CLSD : 1.50 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CLSD with:

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

2nd Resistance Point 1.90
1st Resistance Point 1.70
Last Price 1.49
1st Support Level 1.36
2nd Support Level 1.22

See More

52-Week High 15.33
Fibonacci 61.8% 9.85
Fibonacci 50% 8.16
Fibonacci 38.2% 6.47
Last Price 1.49
52-Week Low 0.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar